EXPLORINEER
ja

アーカイブ — US — techcrunch

Jury says Apple owes Masimo $634M for patent infringement

A federal jury ruled that Apple owes Masimo $634 million for infringing a patent related to blood oxygen monitoring technology in Apple Watches. Masimo views this as a victory for protecting innovation, but Apple plans to appeal, disputing the verdict's validity, citing the patent's expiration in 2022. Legal tensions continue as Masimo pursues further actions against Apple's new implementations of the technology.

要点

  • The jury's decision mandates Apple to pay Masimo $634 million.
  • The case revolves around Apple's Apple Watch technology for blood oxygen monitoring, specifically in workout mode and heart rate notifications, violating Masimo's patent.
  • Masimo claims this ruling is pivotal for protecting their intellectual property for medical innovations.
  • Apple plans an appeal, arguing the patent expired in 2022 and claiming the technology is outdated.
  • Masimo accuses Apple of employee poaching and has been actively litigating against Apple regarding multiple patents.
  • The U.S. International Trade Commission sided with Masimo, leading to the import ban of Apple Watches with blood oxygen features.
  • Progress was made by Apple in August for a new feature implementation to bypass the import ban.
  • Masimo is suing U.S. Customs for allowing Apple Watches with new blood oxygen technology.

なぜ重要か

  • This ruling underscores ongoing tensions in the tech industry regarding patent infringement and intellectual property rights.
  • The legal precedent may influence future cases related to wearable health technology.
  • Emerging IT trends by 2025 suggest a growing emphasis on health tech innovation and robust patent protections in medical device markets.
  • Masimo's legal challenges reflect wider industry practices where large technology companies face scrutiny over their use of innovative technologies developed by smaller firms.

The jury's ruling against Apple signifies a critical moment in the intersection of technology and healthcare, highlighting ongoing disputes over intellectual property rights and innovation protections that could shape future tech developments.